Furthermore, performing experiments in a well-stablished in vivo cancer immunotherapy model responding to agonist anti-CD137 mAb treatment, the BV6 SMC hampered the antitumor efficacy of CD137 agonists. The gene discussed is TNFRSF9; the disease is cancer.